Flumazenil

Flumazenil

Clinical data
Pregnancy category	AU: B3 C
Routes of administration	Intravenous
ATC code	V03AB25 (WHO)
Pharmacokinetic data
Metabolism	Hepatic
Elimination half-life	7-15 min (initial) 20-30 min (brain) 40-80 min (terminal)
Excretion	Urine 90-95% Feces 5-10%
Identifiers
IUPAC name ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo- 4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
CAS Number	78755-81-4
PubChem CID	3373
DrugBank	APRD00974
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C15H14FN3O3
Molar mass	303.288 g/mol

WikiDoc Resources for Flumazenil
Articles
Most recent articles on Flumazenil Most cited articles on Flumazenil Review articles on Flumazenil Articles on Flumazenil in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Flumazenil Images of Flumazenil Photos of Flumazenil Podcasts & MP3s on Flumazenil Videos on Flumazenil
Evidence Based Medicine
Cochrane Collaboration on Flumazenil Bandolier on Flumazenil TRIP on Flumazenil
Clinical Trials
Ongoing Trials on Flumazenil at Clinical Trials.gov Trial results on Flumazenil Clinical Trials on Flumazenil at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Flumazenil NICE Guidance on Flumazenil NHS PRODIGY Guidance FDA on Flumazenil CDC on Flumazenil
Books
Books on Flumazenil
News
Flumazenil in the news Be alerted to news on Flumazenil News trends on Flumazenil
Commentary
Blogs on Flumazenil
Definitions
Definitions of Flumazenil
Patient Resources / Community
Patient resources on Flumazenil Discussion groups on Flumazenil Patient Handouts on Flumazenil Directions to Hospitals Treating Flumazenil Risk calculators and risk factors for Flumazenil
Healthcare Provider Resources
Symptoms of Flumazenil Causes & Risk Factors for Flumazenil Diagnostic studies for Flumazenil Treatment of Flumazenil
Continuing Medical Education (CME)
CME Programs on Flumazenil
International
Flumazenil en Espanol Flumazenil en Francais
Business
Flumazenil in the Marketplace Patents on Flumazenil
Experimental / Informatics
List of terms related to Flumazenil

Flumazenil (also known as flumazepil, code name Ro 15-1788, trade names Anexate, Lanexat, Mazicon, Romazicon) is a benzodiazepine antagonist, used as an antidote in the treatment of benzodiazepine overdose. It reverses the effects of benzodiazepines by competitive inhibition at the benzodiazepine binding site on the GABA_A receptor. It was introduced in 1987 by Hoffmann-La Roche under the trade name Anexate.

The onset of action is rapid and usually effects are seen within one to two minutes. The peak effect is seen at six to ten minutes. The recommended dose for adults is 200 μg every 1-2 minutes until the effect is seen, to a maximum of 3 mg per hour. It is available as a clear, colourless solution for intravenous injection, containing 500 μg in 5 mls.

All benzodiazepines (including midazolam) have longer half-lives than flumazenil. Therefore, repeat doses of flumazenil may be required to prevent recurrent symptoms of overdosage once the initial dose of flumazenil wears off. It is hepatically metabolised to inactive compounds which are excreted in the urine. Subjects who are physically dependent on benzodiazepines may suffer benzodiazepine withdrawal symptoms, including seizure, upon administration of flumazenil.

See also

• Ro15-4513

References

• Romazicon product information, Roche USA

External links

• Template:DailyMed